Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Inclusion Criteria:

• Has completed an enlicitide decanoate (also known as enlictide and MK-0616) parentstudy [MK-0616-013 (NCT05952856), MK-0616-017 (NCT05952869), and MK-0616-018 (NCT06450366)] per protocol (including the final assessments/procedures of theirparent study)

• Had an overall study intervention compliance ≥80% while participating in theirparent study

Exclusion Criteria:

• Has discontinued study intervention in their parent study

• Has an ongoing serious adverse event considered related to study intervention by theinvestigator in the parent study

• Is planning to begin treatment with a nonstudy protein convertase subtilisin/kexintype 9 inhibitor (PCSK9i) while enrolled in the study

• Is currently participating in an interventional clinical study other than anenlicitide decanoate parent study